Dr. Emily Keeling Farrar is a Charleston, South Carolina based female rheumatologist who is specialized in Rheumatology. Active license number of Dr. Emily Keeling Farrar for Rheumatology is SCLL 25389 in South Carolina. Dr. Emily Keeling Farrar treat joint disease similar to orthopedists but do not perform surgeries. She diagnose and treat diseases of joints, muscle, bones and tendons which includes arthritis, back pain, muscle strains, common athletic injuries and 'collagen' diseases.
Complete Profile:
Dr. Emily Keeling Farrar speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Rheumatology
Credentials:
M.D.
Gender:
Female
Practice Address:
171 Ashley Ave, Charleston, South Carolina, 29425-0001
Phone:
843-792-1414
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1841380953
NPI Enumeration Date:
13 Oct, 2006
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Emily Keeling Farrar are as mentioned below.
License Number
Specialization
State
Status
SCLL 25389
Rheumatologist
South Carolina
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
21 Thomas St, Apt A Charleston, South Carolina
Zip:
29403-6058
Phone Number:
843-853-0304
Fax Number:
--
Patients can reach Dr. Emily Keeling Farrar at 171 Ashley Ave, Charleston, South Carolina or can call to book an appointment on 843-792-1414. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.